Centiloid recommendations for clinical context-of-use from the AMYPAD consortium

Collij, Lyduine E.; Bollack, Ariane; La Joie, Renaud; Shekari, Mahnaz; Bullich, Santiago; Roé Vellvé, Núria; Koglin, Norman; Jovalekic, Aleksandar; Vállez García, David; Drzezga, Alexander; Garibotto, Valentina; Stephens, Andrew W.; Battle, Mark; Buckley, Christopher, 1948-; Barkhof, Frederik; Farrar, Gill; Gispert López, Juan Domingo; AMYPAD Consortium

Centiloid recommendations for clinical context-of-use from the AMYPAD consortium

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Collij, Lyduine E.
dc.contributor.author Bollack, Ariane
dc.contributor.author La Joie, Renaud
dc.contributor.author Shekari, Mahnaz
dc.contributor.author Bullich, Santiago
dc.contributor.author Roé Vellvé, Núria
dc.contributor.author Koglin, Norman
dc.contributor.author Jovalekic, Aleksandar
dc.contributor.author Vállez García, David
dc.contributor.author Drzezga, Alexander
dc.contributor.author Garibotto, Valentina
dc.contributor.author Stephens, Andrew W.
dc.contributor.author Battle, Mark
dc.contributor.author Buckley, Christopher, 1948-
dc.contributor.author Barkhof, Frederik
dc.contributor.author Farrar, Gill
dc.contributor.author Gispert López, Juan Domingo
dc.contributor.author AMYPAD Consortium
dc.date.accessioned 2025-09-29T12:34:45Z
dc.date.available 2025-09-29T12:34:45Z
dc.date.issued 2024
dc.description.abstract Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context-of-use recommendations for the CL scale. Compared to histopathology, visual reads, and cerebrospinal fluid, CL quantification accurately reflects the amount of AD pathology. With high certainty, a CL value below 10 excludes the presence of Aβ pathology, while a value above 30 corresponds well with pathological amounts. Values falling in between these two cutoffs ("intermediate range") are related to an increased risk of disease progression. Together, CL quantification is a valuable adjunct to visual assessments of amyloid-PET images. An abnormal amyloid biomarker assessment is a key criterion to determine eligibility for anti-amyloid disease-modifying therapies, and amyloid-PET quantification can add further value by precisely monitoring amyloid clearance, and hence guiding patient management decisions. HIGHLIGHTS: Centiloid (CL) quantification robustly reflects of the amount of Aβ pathology. CL < 10/CL > 30 reflects Aβ-negativity/positivity thresholds with high certainty. CL quantification is a valuable adjunct to visual assessments of amyloid-PET. CL quantification can support trial design and treatment management. CL quantification could support the identification of early or emerging Aβ pathology.
dc.description.sponsorship The project leading to this paper has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115952. This joint undertaking receives the support from the European Union's Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
dc.format.mimetype application/pdf
dc.identifier.citation Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Roé-Vellvé N, et al. Centiloid recommendations for clinical context-of-use from the AMYPAD consortium. Alzheimers Dement. 2024 Dec;20(12):9037-48. DOI: 10.1002/alz.14336
dc.identifier.doi http://dx.doi.org/10.1002/alz.14336
dc.identifier.issn 1552-5260
dc.identifier.uri http://hdl.handle.net/10230/71286
dc.language.iso eng
dc.publisher Wiley
dc.relation.ispartof Alzheimers Dement. 2024 Dec;20(12):9037-48
dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/115952
dc.rights © 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.subject.keyword Amyloid‐β
dc.subject.keyword Centiloid quantification
dc.subject.keyword Clinical trials
dc.subject.keyword Positron emission tomography
dc.title Centiloid recommendations for clinical context-of-use from the AMYPAD consortium
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)
Articles (Departament de Medicina i Ciències de la Vida)
Documents OpenAIRE (Open Access Infrastructure for Research in Europe)